Amgen and AbbVie Shine Amid Healthcare Dividend Drought

Despite challenges in the healthcare sector for reliable dividends, Amgen and AbbVie stand out with strong dividend policies and significant revenue growth. Both companies showcased resilience, making them appealing options for investors seeking reliable income.

Date: 05-04-2025

AI Rating: 7

Overview of the Healthcare Sector
Healthcare stocks often attract scrutiny due to their limited dividend offerings and high capital requirements associated with drug development. Yet, Amgen and AbbVie are notable exceptions with favorable dividend policies. Indeed, both companies have recently announced increases in their dividends, reflecting their confidence and commitment towards rewarding shareholders.

Amgen's Performance
Amgen experienced a remarkable year, with overall revenue rising 19% to over $33.4 billion, driven by significant sales growth in several blockbuster drugs. Notably, high cholesterol treatment Repatha saw a 36% increase in sales, illustrating strong demand in a high-growth therapeutic area. It's important to note that while the net income dropped to about $4.1 billion from $6.7 billion due to rising research expenses, the company's healthy revenue growth and dividend hike to $2.38 per share indicate a balanced approach to maintaining shareholder value despite increased operational costs.

AbbVie's Resilience
Similarly, AbbVie reported a nearly 4% rise in total net revenue to $56.3 billion, showcasing the company's ability to maintain a solid revenue trajectory despite challenges like losing U.S. patent exclusivity for its blockbuster drug Humira. However, it has pivoted successfully by growing its portfolio, particularly with drugs like Rinvoq and Skyrizi. The company has maintained robust cash flow, and with its dividend increase to $1.64 per share, it reinforces its longstanding commitment to dividend payments while broadcasting confidence in future performance, underscored by management's guidance for a compound annual growth rate (CAGR) in revenue in the high single-digit percentages through 2029.

Implications for Investors
Both companies demonstrate robust revenue growth, albeit with pressure on profit margins due to escalating costs. For professional investors, the dividend payments represent a key attraction in the current low-yield environment. Amgen's and AbbVie's performances suggest potential resilience against sector headwinds, positioning them as favorable investments over the near-term holding period of 1 to 3 months.

Stocks: AMGN ABBV